Price$2.12-0.08 (-3.85%)
03:30 PM07:45 PM
News · 26 weeks73-33%
2026-03-012026-08-23
Mix3790d
- Insider19(51%)
- SEC Filings8(22%)
- Other5(14%)
- Leadership2(5%)
- Earnings2(5%)
- Analyst1(3%)
Latest news
25 items- PR1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.Dr. Thaïs Aliabadi, a board-certified OB-GYN and co-host of the SHE MD podcast, makes the case that preterm birth risk is personal, knowable between weeks 18 and 21 of pregnancy, and worth a direct conversation with your doctor. She points to a simple blood test, the PreTRM® Test from Sera Prognostics, and PRIME trial results showing early, low-cost intervention can cut the earliest preterm births by more than half.SALT LAKE CITY and LOS ANGELES, Aug. 25, 2026 /PRNewswire/ -- Preterm birth affects about 1 in 10 U.S. pregnancies. It's one of the most common pregnancy complications. It's also one nobody warns you about. Yet most expecting mothers never learn their own risk until something goes
- SECSera Prognostics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- PRSERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICERSALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced today that Scott Gleason has been appointed Chief Financial Officer (CFO), effective August 31, 2026. Mr. Gleason brings more than 25 years of healthcare, diagnostics, and capital markets experience to Sera. Most recently, he served as Vice President of Investor Relations and Treasury at Neogen Corporation and previously served as CFO of LarmorBio and NX Prenatal. He also served as th
- SECSEC Form 10-Q filed by Sera Prognostics Inc.10-Q - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- SECSera Prognostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- PRSERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTSSALT LAKE CITY, Aug. 12, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter ended June 30, 2026. Key Second Quarter and Recent Highlights:Advanced Commercial Adoption Strategy with Fourth Partnership Program Launch: In August 2026, we launched fourth partnership program, expanding implementation of PreTRM® Test-guided care through a state-based initiative with a national payer. We also exceeded our 2026 payer eng
- PRSERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026SALT LAKE CITY, July 29, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report second quarter fiscal year 2026 financial results on Wednesday August 12, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.
- INSIDERDirector Phillips Joshua was granted 24,686 shares, increasing direct ownership by 43% to 81,691 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Mirza Mansoor Raza was granted 24,197 shares, increasing direct ownership by 42% to 81,937 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Lawrence Sandra Aj was granted 24,702 shares, increasing direct ownership by 150% to 41,175 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Kamdar Kim P. was granted 25,847 shares, increasing direct ownership by 79% to 58,420 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Critchfield Gregory C was granted 24,020 shares, increasing direct ownership by 3% to 846,886 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Capone Mark Christopher was granted 44,379 shares (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERDirector Barlow Jane F was granted 24,375 shares, increasing direct ownership by 107% to 47,088 units (SEC Form 4)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- PRPRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE-- Study Highlights Screening Efficiency and Potential Cost Savings in a Large Underserved Population --SALT LAKE CITY, July 9, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced publication of a new subgroup analysis from the PRIME randomized controlled trial. The analysis demonstrated that PreTRM® Test-guided care in first-time pregnancies significantly improved neonatal outcomes, including a 22% reduction in neonatal intensive care unit (NICU) admissions. Because NICU care
- INSIDERSEC Form 3 filed by new insider Capone Mark Christopher3 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- SECSera Prognostics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
- PRSERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORSSALT LAKE CITY, June 30, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Mark Capone will join its Board of Directors, effective July 1, 2026. Mr. Capone is a seasoned healthcare executive with more than 40 years of leadership experience across the diagnostics and life sciences sectors, including extensive service on private and public company boards and committees. In his last operating role, he served as Chief Executive Officer of Myriad Genet
- PRSERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTHSALT LAKE CITY, June 24, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced its participation in a multi-institutional research program that was awarded up to $10.4 million by the Advanced Research Projects Agency for Health (ARPA-H) to develop a novel point-of-care diagnostic test designed to improve the safety of labor and delivery. The award, part of ARPA-H's Making Obstetrics Care Smart (MOCS) program, supports a collaboration led by researchers at the University of Califo
- PRSERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY--Aligns With Growing Focus on Early Identification and Management of Preterm Birth Risk--SALT LAKE CITY, June 23, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today acknowledged recent legislative action in Illinois aimed at expanding access to evidence-based approaches for identifying and managing the risk of preterm birth among pregnant individuals. The legislation amends the Illinois Public Aid Code to require the state's medical assistance program (Medicaid) to provide coverage and
- INSIDERChief Financial Officer Aerts Austin sold $4,094 worth of shares (2,037 units at $2.01), decreasing direct ownership by 0.67% to 301,190 units (SEC Form 4) (tax withholding)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Commercial Officer Anderson Dyaarl Lee Jr. sold $9,525 worth of shares (4,739 units at $2.01), decreasing direct ownership by 6% to 77,998 units (SEC Form 4) (tax withholding)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERGeneral Counsel Jackson Benjamin sold $4,380 worth of shares (2,179 units at $2.01), decreasing direct ownership by 1% to 161,756 units (SEC Form 4) to satisfy tax liability4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Medical Officer Inglis Tiffany Eul Davis sold $728 worth of shares (362 units at $2.01), decreasing direct ownership by 0.39% to 92,075 units (SEC Form 4) (tax liability)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
- INSIDERChief Executive Officer Lindgardt Zhenya sold $14,050 worth of shares (6,990 units at $2.01), decreasing direct ownership by 0.80% to 865,009 units (SEC Form 4) (tax withholding)4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
SERA FAQ
7 questionsWhat does Sera Prognostics Inc. do?
Sera Prognostics, Inc., a health diagnostic company, discovers, develops, and commercializes biomarker tests for the early prediction of preterm birth risk and other complications of pregnancy. It develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Where does SERA stock trade?
Sera Prognostics Inc. (SERA) is listed on NASDAQ.What sector and industry is SERA in?
Sera Prognostics Inc. operates in the Health Care sector, Medical Specialities industry.When did Sera Prognostics Inc. go public?
Sera Prognostics Inc. (SERA) completed its IPO in 2021.What are analysts saying about SERA?
Sera Prognostics Inc. has had 8 recent analyst actions on file. The most recent action was from Craig Hallum: Buy with a $600.00 price target on 2026-06-04. Recent price targets range from $400.00 to $1900.00.What companies are similar to SERA?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare SERA side-by-side with any of them on Quantisnow.How can I track SERA on Quantisnow?
Quantisnow aggregates Sera Prognostics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SERA to receive live email and push alerts on every new disclosure.